Cell & Gene Therapy Outsourcing Process Development
Source: Life Science Leader
By Industry Standard Research
Half of respondents who outsource cell and/or gene manufacturing activities to CDMOs are outsourcing process development to ensure the ability to scale up manufacturing should the therapy advance toward commercialization. Respondents from large biopharma companies are slightly more likely to outsource this activity in the near future when compared to respondents from nonlarge biopharma companies (52% vs 45%).
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more